OTLK
Outlook Therapeutics, Inc.
There isn't enough reported data to score OTLK yet.
OTLK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
OTLK's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
OTLK PE Valuation
OTLK has no meaningful PE right now: it lost money over the past year.
OTLK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OTLK's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OTLK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$10.70 | -$5.70 |
| Q1 2024 | -$11.41 | -$6.41 |
| Q4 2023 | -$4.00 | +$2.20 |
| Q3 2023 | -$4.80 | +$1.40 |
| Q2 2023 | -$5.00 | +$1.40 |
| Q1 2023 | -$5.00 | +$1.20 |
| Q4 2022 | -$6.20 | $0.00 |
| Q3 2022 | -$6.20 | +$0.80 |
OTLK is still losing money, but far less than before: $1.10 per share over the past year, against $57.80 at its worst in late 2019.
OTLK Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -1046% | N/A |
| Q3 2019 | -217% | N/A |
OTLK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$21M | -$9.1M |
| Q1 2026 | -$7.8M | +$8.8M |
| Q4 2025 | -$14.9M | -$4M |
| Q3 2025 | -$12.4M | +$4.6M |
| Q2 2025 | -$11.9M | +$7.6M |
| Q1 2025 | -$16.6M | +$2.7M |
| Q4 2024 | -$11M | +$2.1M |
| Q3 2024 | -$17M | -$4.2M |
OTLK has burned cash in almost every quarter: −$56M over the past year, against −$56M the year before.
OTLK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +67% | +54.9M shares |
| 1 year | +270% | +99.8M shares |
| 3 years | +966% | +124M shares |
| 5 years | +2146% | +131M shares |
OTLK has 137M diluted shares, up 270% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | — |
OTLK Net Leverage
OTLK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OTLK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.7 | Neutral |
| Stochastic | 3.6 | Oversold |
OTLK's weekly RSI is 38 (neutral) and its Stochastic is 4 (oversold).
OTLK PE vs Healthcare Sector
OTLK has no meaningful PE right now: it lost money over the past year.
OTLK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.52 | 15% below |
| 20 week MA | $0.80 | 45% below |
| 50 week MA | $0.76 | 42% below |
| 100 week MA | $1.20 | 63% below |
| 200 week MA | $7.29 | 94% below |
OTLK is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
OTLK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.8 | $31.0 | +188% |
| 2021 | $31.0 | $27.6 | -11% |
| 2022 | $27.6 | $21.4 | -22% |
| 2023 | $21.4 | $7.88 | -63% |
| 2024 | $7.88 | $2.01 | -74% |
| 2025 | $2.01 | $1.82 | -9.5% |
| 2026 YTD | $1.82 | $0.44 | -76% |
OTLK has finished five years in a row lower, and it's down 76% so far in 2026.